Recursive cumulative meta-analysis: A diagnostic for the evolution of total randomized evidence from group and individual patient data

Journal of Clinical Epidemiology

Volumn 52, Issue 4, 1999, Pages 281-291

  Loannidis, John P A ^a,b   Contopoulos Ioannidis, Despina G ^c,d   Lau, Joseph ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (Greece)

Author keywords

Bias; Meta analysis; Publication bias; Randomized trials; Study design

Indexed keywords

ARTICLE; DATA ANALYSIS; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION PROCESSING; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT OUTCOME;

ACYCLOVIR; ANTIVIRAL AGENTS; HIV INFECTIONS; HUMANS; META-ANALYSIS; METHODS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0033120540     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(98)00159-0     Document Type: Article

References (49)

1. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990; 263: 1385-1389.
2. loannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279: 281-286.
3. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med 1995; 14: 2057-2079.
4. Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 1993; 341:418-422.
5. Steinberg KK, Smith SJ, Stroup DF, Olkin I, Lee NC, Williamson GD, et al. Comparison of effect estimates from a metaanalysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. Am J Epidemiol 1997; 145: 917-925.
6. Franzosi MG, Santoro E, Santoro L, and ACE-Inhibitor Collaborative Group. Prospective meta-analysis using individual patient data vs. meta-analysis of published reports: The case of ACE-inhibitors in myocardial infarction. Control Clin Trials 1997; 18: 183S.
7. Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative metaanalysis of trials of treatments for myocardial infarction. N Engl J Med 1992; 327: 248-254.
8. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis builds evidence for exemplary medical care. J Clin Epidemiol 1995; 48: 45-57.
9. Berkey CS, Mosteller F, Lau J, Antman EM. Uncertainty of the time of first significance in random effects cumulative meta-analysis. Control Clin Trials 1996; 17: 357-371.
10. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
11. Der Simonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
12. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall; 1984.
13. Lau J, loannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 126: 820-826.
14. loannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection. J Infect Dis 1998; 178: 349-359.
15. Cooper DA, Pedersen C, Aiuti F, Vilde JL, Ruhnke M, Pehrson PO, et al. The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. AIDS 1991; 5: 933-943.
16. Cooper DA, Pehrson O, Pedersen C, Moroni M, Oksenhehdler H, Rozenbaum W, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind, randomized trial. AIDS 1993; 7: 197-207.
17. Youle MS, Gazzard BG, Johnson MA, Cooper DA, Hoy JF, Busch H, et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994; 8: 641-649.
18. Chavanet P, Malet J, Wladner A, Aho S, Buisson M, Biefeld P, et al. A double-blind randomized placebo trial on very high doses of acyclovir in weakly symptomatic HIV-patients. Cancer Detect Prev 1990; 14: 669-673.
19. Collier AC, Bozzette S, Coombs RW, Causey DM, Schoenfeld DA, Spector SA, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323: 1015-1021.
20. Lavelle J, Lang W, Lefkowitz L, et al. A randomized trial comparing zidovudine alone and in combination with acyclovir for treatment of early symptomatic HIV infection. In: Abstracts of the VIII International Conference on AIDS, Amsterdam, 1992. (Abstract PoB 3585)
21. Cooper DA, Gazzard GB, Stevens J, Bell AR. The effect of acyclovir cotherapy on survival in individuals with advanced HIV disease. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994 Oct 4-7. (Abstract 61)
22. Collier AC, Schoenfeld DA, Bourland D, Hirsch M, Davis LG, Corey L. Prospective comparative study of acyclovir and zidovudine versus zidovudine alone in patients with AIDS. In: Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections, January 29-February 2, 1995. (Abstract 383)
23. Smith GD, Egger M. Meta-analysis. Unresolved issues and future developments. BMJ 1998; 316: 221-225.
24. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin inhibitors: Meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-687.
25. Nakielny J. Effective and acceptable treatment for depression. BMJ 1993; 306: 1125.
26. Mulder JW, de Wolf F, Goudsmit J, et al. Long-term zidovudine treatment of asymptomatic HIV-1 infected subjects. Antiviral Res 1990; 13: 127-138.
27. Luxton JC, Williams I, Weller I, Crawford DH. Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment. AIDS 1993; 7: 1337-1343.
28. Collier AC, Schoenfel D, Hirsch M, et al. Lack of effect on survival of high-dose acyclovir and zidovudine compared with zidovudine alone for acquired immunodeficiency syndrome. Antiviral Ther 1998; 3: 25-32.
29. Schmid CH, Lau J, Mclntosh M, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in a meta-analysis of clinical trials. Stat Med. 1998; 17: 1923-1942.
30. ISIS-4 Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
31. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Ann Intern Med 1995; 123: 873-877.
32. Hughes MD, Freedman LS, Pocock SJ. The impact of stopping rules on heterogeneity of results in overviews of clinical trials. Biometrics 1992; 48: 41-53.
33. Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med 1988; 7: 1231-1242.
34. Pocock SJ, Hughes MD. Practical problems in interim analyses, with particular regard to estimation. Control Clin Trials 1989; 10(Suppl. 4): 209S-221S.
35. Lau J, loannidis JP, Schmid CH. Summing up evidence: One answer is not always enough. Lancet 1998; 351: 123-127.
36. Pogue JM, Yusuf S. Cumulative evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 1997; 18: 580-593.
37. Bero L, Rennie D. The Cochrane Collaboration. JAMA 1995; 274: 1935-1938.
38. Villar J, Carroli G, Belizan JM. Predictive ability of meta-analysis of randomized controlled trials. Lancet 1995;345: 772-776.
39. Cappelleri JC, loannidis JPA, Schmid CH, et al. Large trials versus meta-analyses of small trials: How do their results compare? JAMA 1996; 276: 1332-1338.
40. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337: 536-542.
41. Ioannidis JPA, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. JAMA 1998; 279: 1089-1093.
42. Rothwell PM, Robertson G. Meta-analyses of randomised controlled trials. Lancet 1998; 350: 1181-1182. (Letter)
43. Egger M, Smith GD, Sterne JAC. Meta-analysis: Is moving the goal post the answer? Lancet 1998; 351: 1517.
44. loannidis JP, Cappelleri JC, Lau J, Skalnik PR, Melville B, Chalmers TC, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: A meta-analysis. Ann Intern Med 1995; 122: 856-866.
45. Ioannidis JP, Bassett R, Hughes MD, Valbenting PA, Sacks HS, Lau J. Predictors and impact of patients lost to follow-up in a long-term trial of early versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 22-30.
46. McIntosh M. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med 1996; 15: 1713-1728.
47. Ioannidis JP, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates: An example from trials of human immunodeficiency virus infection. Am J Epidemiol 1996; 144: 1074-1085.
48. Ioannidis JP, Lau J. The impact of high risk patients on the results of clinical trials. J Clin Epidemiol 1997; 50: 1089-1098.
49. Yusuf S, Wites J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-98.